Biotechnology Program, School of Bioresources and Technology, King Mongkut's University of Technology Thonburi (Bangkhunthian), Bangkok, 10150, Thailand.
Pilot Plant Development and Training Institute, King Mongkut's University of Technology Thonburi (Bangkhunthian), Bangkok, 10150, Thailand.
Mol Biotechnol. 2022 Dec;64(12):1409-1418. doi: 10.1007/s12033-022-00519-8. Epub 2022 Jun 15.
Neuraminidase (NA) is a second major surface protein of the influenza virus and has recently been suggested as a supplemental antigen to the major immunodominant hemagglutinin (HA) antigen in the influenza vaccine. NA is less affected by antigenic drift compared to the HA, induces strong anti-neuraminidase immune responses, and provides broader protection against many influenza strains. However, the NA amount in currently licensed influenza virus vaccines is much lower than that of HA, and not standardized. A platform to produce NA antigen, in the form of virus-like particles (VLPs), was thus developed, to facilitate supplementation of NA antigen in the influenza vaccine formula. Stably transformed Sf9 insect cells had been engineered to express the influenza A virus (H5N1) NA gene under a baculovirus OpMNPV IE2 promoter. Recombinant NA protein was synthesized and assembled into VLPs, in the intact cellular environment provided by insect cells. Approximately 150 µg/ml of NA-VLPs was obtained in the culture medium. Purification of the NA-VLPs was achieved by a sucrose density gradient ultracentrifugation. The purified NA-VLPs effectively induced anti-NA antibodies with neuraminidase inhibition activities in mice. This work demonstrates a simple process to produce an immunocompetent NA-VLPs antigen, exclusively made of only neuraminidase, by insect cells.
神经氨酸酶(NA)是流感病毒的第二种主要表面蛋白,最近被提议作为流感疫苗中主要免疫显性血凝素(HA)抗原的补充抗原。与 HA 相比,NA 的抗原漂移受影响较小,可诱导强烈的抗神经氨酸酶免疫反应,并提供针对许多流感株的更广泛保护。然而,目前许可的流感病毒疫苗中的 NA 含量远低于 HA,且未标准化。因此,开发了一种生产 NA 抗原(以病毒样颗粒 (VLPs) 的形式)的平台,以促进流感疫苗配方中 NA 抗原的补充。通过稳定转化的 Sf9 昆虫细胞,在杆状病毒 OpMNPV IE2 启动子的控制下表达了流感 A 病毒(H5N1)NA 基因。在昆虫细胞提供的完整细胞环境中,合成并组装了重组 NA 蛋白成 VLPs。在培养基中获得了约 150µg/ml 的 NA-VLPs。通过蔗糖密度梯度超速离心纯化了 NA-VLPs。纯化的 NA-VLPs 有效地诱导了具有神经氨酸酶抑制活性的抗-NA 抗体在小鼠中。这项工作展示了一种通过昆虫细胞生产仅由神经氨酸酶组成的免疫原性 NA-VLPs 抗原的简单过程。